Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR formulations is crucial to ensuring their efficacy and safety. Sometimes modified drug release formulations are also designed to alter the location where the drug is released, in addition to the timing of the release of the medication.

The in vivo bioavailability of MR formulations is assessed by measuring the fraction of the drug absorbed, potential dose dumping, food effects, circadian influences, sustained therapeutic levels, steady-state concentration ratios, and percent fluctuation.

Single-dose studies are conducted to evaluate the absorption profile of the MR formulation and detect any risk of dose dumping, which refers to the unintended rapid release of the drug that could lead to toxicity. These studies involve pharmacokinetic analysis, including measuring the maximum plasma concentration (C_max), time to reach C_max (t_max), and the area under the concentration-time curve (AUC), which reflects total drug exposure.

Multiple-dose studies focus on assessing the MR formulation's ability to maintain sustained therapeutic levels over extended periods. They help determine steady-state plasma concentrations, which are achieved when the rate of drug administration equals the rate of elimination. Parameters such as the steady-state concentration ratio and percentage fluctuation are critical in evaluating the formulation's ability to minimize peaks and troughs in drug levels, thereby reducing side effects and enhancing therapeutic efficacy.

To ensure consistency and effectiveness, MR formulations are compared to reference standards such as solutions, suspensions, or existing MR products with well-established pharmacokinetics. In addition, in vitro bioequivalence tests are conducted before in vivo studies to simulate gastrointestinal conditions. These tests assess the impact of variables such as pH variations, fed versus fasted states, and the presence of bile or pancreatic secretions on drug release. Such in vitro assessments are critical for predicting in vivo performance and ensuring that the formulation meets regulatory bioequivalence criteria before advancing to clinical testing.

By integrating in vivo bioavailability studies with in vitro bioequivalence assessments, researchers can optimize MR formulations to achieve consistent drug release, improve therapeutic outcomes, and minimize variability in patient response.